` ELAB (ELEVAI Labs Inc) vs S&P 500 Comparison - Alpha Spread

ELAB
vs
S&P 500

Over the past 12 months, ELAB has underperformed S&P 500, delivering a return of -100% compared to the S&P 500's 8% growth.

Stocks Performance
ELAB vs S&P 500

Loading
ELAB
S&P 500
Add Stock

Performance Gap
ELAB vs S&P 500

Loading
ELAB
S&P 500
Difference

Performance By Year
ELAB vs S&P 500

Loading
ELAB
S&P 500
Add Stock

Competitors Performance
ELEVAI Labs Inc vs Peers

S&P 500
ELAB
KVUE
NTCOY
1318
ODD
Add Stock

ELEVAI Labs Inc
Glance View

Market Cap
1.6m USD
Industry
Consumer products

ELEVAI Labs Inc is a US-based company operating in Personal Care Products industry. The company is headquartered in Newport Beach, California. The company went IPO on 2023-11-21. Elevai Labs, Inc. is a physician-dispensed skincare company. The firm conducts research and development to advance science-driven topical skincare that complements the medical aesthetics industry. The company produces and commercializes topical skincare products that contain its proprietary stem cell derived Elevai Exosomes designed to enhance the appearance of skin. Its Precision Regenerative Exosome Technology (PREx) biotechnology process yields exosome lots from human umbilical cord-derived mesenchymal stem cells (hUMSC) for its specialty physician-dispensed skincare products. The company has integrated the use of stem cell exosomes into its initial product line: Elevai Post Treatment E-Series. The E-Series comprises two post-skincare procedure care products that target the face and neck, and upper chest regions. Its products include Empower and Enfinity serums. Empower is its after-treatment topical product that supports the appearance of healthy skin and promotes an even toned complexion.

ELAB Intrinsic Value
6.62 USD
Undervaluation 66%
Intrinsic Value
Price
E
Back to Top